The Online Investor
Drugs & Pharmaceuticals M&A image Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Mon., Nov. 28, 10:24 AM Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.

Slide #75. Columbia Laboratories Molecular Profiles Ltd.

Acquirer: Columbia Laboratories (CBRX)
Acquiree: Molecular Profiles Ltd.
Details: Columbia Laboratories Inc. (NasdaqCM:CBRX) ["Columbia", the "Company"] has acquired Molecular Profiles Ltd. ["Molecular Profiles"], a privately-held, cash-flow positive, U.K.-based pharmaceutical development services company, for total consideration of approximately $25.0 million comprising $16.7 million in cash and 1,051,323 shares of Columbia common stock, representing ten to eleven times Molecular Profiles' projected EBITDA1 for its fiscal year ending July 31, 2014. The newly issued shares are subject to a twelve-month lock-up period. Excluding transaction costs, the acquisition is expected to be immediately accretive. Additionally, Columbia expects to realize a double-digit impact to its EBITDA1 and operational synergies of up to $400,000 annually. This acquisition was unanimously approved by the Boards of Directors of both companies and received the approval of Molecular Profiles' shareholders. No further approvals are anticipated to be required. In addition, Molecular Profiles' CEO and co-founder, Dr. Nikin Patel, will join Columbia's Board of Directors.

Juniper Pharmaceuticals is engaged in in the business of developing, licensing, manufacturing and selling to its marketing partners pharmaceutical products that utilize its drug delivery technologies to treat various medical conditions. Co.'s products include bioadhesive vaginal gel products for infertility, pregnancy support, amenorrhea, and other women's health conditions, and a bioadhesive buccal system for male hypogonadism. Co. has partnered or sold each of these products for commercialization in various regions of the world. All of the products Co. has developed utilize its Bioadhesive Delivery System, which consists principally of a polymer (polycarbophil) and an active ingredient.

Open the CBRX Page at The Online Investor »

Company Name: 
Juniper Pharmaceuticals Inc
Stock buyback: 
CBRX buyback
Drugs & Pharmaceuticals

Open the CBRX Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree CBRX Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Buy (3.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Drugs & Pharmaceuticals M&A - Slide 75 of 100 Page |

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.